Iran’s Pharmaceutical Sectoral Innovation System

Authors

Abstract:

Abstract By reviewing economic performance, two main phenomena could be identified: The first phenomenon is prior to the third wave of the Industrial Revolution in which limited resources are the predominant input; in other words, physical and natural resources are much more credited than human resources. The second phenomenon resonates with the third wave of industrial revolution to the present time, suggesting the pivotal role of humans in production and accumulation of wealth, in which limited resources are no longer considered as predominant input. The present research seeks to understand the behavioral logic of the players of Iran's pharmaceutical sector so as to infer the innovative treatment of the firms in this sector. The concept of innovative system is indebted to the efforts economists and other scientists have made by analyzing economic development based upon technological development. Meanwhile, sectoral innovation system (SIS) is a tool for analyzing a technological sector in the context of evolutionary economics with an emphasis on institutional capabilities. The structure of such an approach is composed of some components through which performance analysis of certain technological sector could be made possible. In research, we use expert panel with 12 experts from Universities, Companies, Governmental institutes. The current study wishes to explain structural model of institutional elements in this technological sector. Subsequently, in light of such an explanation, structural elements of this sector would be analyzed through identification of legal and regulatory framework, innovative culture, innovative infrastructure, financial resources, information resources, technology transfer mechanisms, commercialization support and marketing.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Innovation and Sectoral Employment

The question whether technological progress displaces employment or whether technological advance is beneficial for the level of employment has been in the core of economic dispute for over two centuries. The beneficial might be achieved by several compensation mechanisms within the economic system. In this paper we categorize these compensation mechanisms into two basic categories that reflect...

full text

Regional, Sectoral Innovation Systems

Today, knowledge economies are a key asset for global competitiveness. Biotechnology is a knowledge-driven sector because it consists of knowledge working on knowledge to create value, decoding in genomics and proteomics being paradigmatic knowledge-based economic activity. Like many other new economy industries such as information and communications technology, new media, and advanced finance,...

full text

Green Buildings in Singapore; Analyzing a Frontrunner’s Sectoral Innovation System

The building sector in Singapore consumes up to half of the nation’s total energy. The government has therefore been urging the transformation of the industry by targeting 80% of all buildings to be green-certified by 2030. Thus far, Singapore has done relatively well, and is widely viewed as frontrunner in this respect. This paper addresses the question: what are the benefits and limitations o...

full text

Knowledge Flows and Delays in the Pharmaceutical Innovation System

Introduction This paper presents an analysis of knowledge flows in the pharmaceutical innovation process. Backward citations, citations to non-patent literature (NPL), and forward citations that link patents, scientific publications, and pharmaceutical pipelines data on drug developments are analyzed and visualized to provide a more holistic understanding. Results show that patents linked to dr...

full text

Did Medicare Induce Pharmaceutical Innovation?

The introduction of Medicare in 1965 was the single largest change in health insurance coverage in U.S. history. Providing nearly universal public health insurance coverage for the elderly, it is currently one of the largest health insurance programs in the world. Its introduction had dramatic effects on health insurance coverage and health care utilization for the elderly (Benjamin Cook et al....

full text

Public Policy and Pharmaceutical Innovation

Historically, new drug introductions have played a central role in medical progress and the availability of cost-effective therapies. Nevertheless, public policy toward pharmaceuticals has been characterized in recent times by increasingly stringent regulatory controls, shorter effective patent terms, and increased encouragement of generic product usage. This has had an adverse effect on the in...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 5  issue 3

pages  257- 276

publication date 2017-10-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023